TGelBio

We develop solutions
for more effective drug delivery

TGel Bio Co., Ltd. is advancing
the field by leveraging its proprietary technologies
in Temperature-Responsive Hydrogels and nanoparticle-based
drug delivery systems to effectively deliver a wide range
of therapeutic agents(drugs) including local anesthetics.

History

Passion for technology,
leading to the future of treatment

2024-2025
  • PF-72 selected for New Medical Technology Evaluation Exemption, sales commenced (July '25)
  • ez:AP domestic and international sales
  • Preparing for commercialization of subsequent products
2020-2023
  • Drug Delivery Device (PF-72) MFDA product approval completed (Nov. '21)
  • Animal Medical Device (ez:AP) APQA approval completed (Nov. '22)
2017-2019
  • Medical Device GMP (Surgical Supplies) Conformity Certification
  • Medical Device Manufacturing and Export Manufacturing Licenses obtained
  • New Technology Certification: PF-72 Technology Certification (2019, Ministry of Trade, Industry and Energy)
2014-2016
  • TGel Bio Inc. established (May 29, 2014)
  • Drug delivery system formulation and production process development
  • Initiated medical device approval (PF-72, surgical supplies)
  • TGel Bio Inc. Corporate R&D Center established
  • Acquired Venture Business Certification
List of awards

Beyond Records,
we set new standards.

Acquisition of New Excellent Technology (NET)
Certification (Dec 19,2019)
New Technology Name
Temperature-Responsive Hydrogel Technology
for Sustained-Release Drug Delivery to relieve postoperative pain
Certifying Authority
Ministry of Trade, Industry and Energy
(3rd New Technology Certification in 2019)